BELIEF Data May Dispel "Placebo Effect" Shadow Over Eclipse PTMR
This article was originally published in The Gray Sheet
Executive Summary
Results from the "Blinded Evaluation of Laser 'PTMR' Intervention Electively For angina pectoris" (BELIEF) trial may represent a key step in restoring faith in the clinical efficacy of percutaneous transmyocardial revascularization and dispelling doubts raised that the therapy has no benefits beyond a placebo effect.
You may also be interested in...
Eclipse Axcis PTMR Clinical Data Could Bring Approval In September
Eclipse Surgical expects the PMA for its Axcis percutaneous transmyocardial revascularization (PTMR) device to receive less resistance from FDA's Circulatory System Devices Advisory Panel than was encountered in the review of the company's TMR product in 1998.
Eclipse Axcis PTMR Clinical Data Could Bring Approval In September
Eclipse Surgical expects the PMA for its Axcis percutaneous transmyocardial revascularization (PTMR) device to receive less resistance from FDA's Circulatory System Devices Advisory Panel than was encountered in the review of the company's TMR product in 1998.
Laser Myocardial Therapies Under The Beam In Light Of J&J DIRECT Results
Results of a Johnson & Johnson-sponsored trial showing that direct myocardial revascularization (DMR) technology has a placebo-comparable effect should prompt FDA to take a closer look at laser therapies for advanced heart disease patients, trial investigators suggest.